Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform, Verisome®.

IBI's Verisome® drug delivery technology is the most advanced, yet simplest system for controlling the release of intraocular therapeutic agents in the eye for extended periods of time. Its unmatched versatility can support products individually formulated to meet the specific clinical requirements of a given active agent targeting a specific ophthalmic disease.

IBI's current portfolio consists of seven (7) proprietary products, all targeting significant unmet ophthalmic medical needs. Over 300 patients have been administered products based on the Verisome® drug delivery technology.

Contact Icon Bioscience, Inc.

65

David S. Tierney, M.D.
Chief Executive Officer
1253 Reamwood Avenue
Sunnyvale, California 94089

United States

Tel: 650-369-4049

Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089 | 650-369-4049
Copyright © 2014 Icon Bioscience, Inc. · Optimization by MME ·